

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 November 2005 (03.11.2005)

PCT

(10) International Publication Number
WO 2005/103239 A3

(51) International Patent Classification:

C12N 9/04 (2006.01) C12N 15/31 (2006.01)

(21) International Application Number:

PCT/EP2005/002557

(22) International Filing Date: 10 March 2005 (10.03.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10 2004 014 274.2 22 March 2004 (22.03.2004) DE

(71) Applicant (for all designated States except US): **DE-GUSSA AG** [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SCHULZE, Renate** [DE/DE]; Bachgasse 49, 64625 Bensheim (DE).


LORENZ, Patrick [DE/DE]; Nibelungenstrasse 91, 64653 Lorsch (DE). **ECK, Jürgen** [DE/DE]; Jakobsweg 48, 64625 Bensheim (DE). **MAY, Oliver** [DE/DE]; Am Rebenborn 17A, 60388 Frankfurt (DE). **GRÖGER, Harald** [DE/DE]; Akademiestrasse 31, 63450 Hanau (DE). **TRAUTHWEIN, Harald** [DE/DE]; Leonrodstrasse 78, 80636 München (DE).

(74) Common Representative: **DEGUSSA AG**; Intellectual Property Management, Patente und Marken, Standort Hanau, Postfach 13 45, 63403 Hanau (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: NOVEL ALCOHOL DEHYDROGENASES



Overview of cluster 2 (= primer group 2), based on 33 sequences

(57) Abstract: The invention relates to novel polypeptides which have the biological activity of an NAD- or NADP-dependent alcohol dehydrogenase. The invention furthermore relates to nucleic acids encoding said polypeptides, to non-human hosts or host cells and to reaction systems which may be used for preparing desired products. The polypeptides of the invention are preferably used in the preparation, starting from aldehydes or ketones, of primary and enantiomerically pure secondary alcohol's which may serve as intermediates for medicaments. Alternatively, the polypeptides of the invention may also be employed in the reverse reaction, i.e. the oxidation of alcohol's with the formation of aldehydes or ketones.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR). — *with amended claims*

(88) Date of publication of the international search report:
9 March 2006

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Date of publication of the amended claims: 27 April 2006

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

AMENDED CLAIMS

[received by the International Bureau on 27 January 2006 (27.01.06);
original claim 1 replaced by new claims 1; remaining claims unchanged (3 pages)]

1. A polypeptide which has the biological activity of
an NAD- or NADP-dependent alcohol dehydrogenase
5 and which comprises or has one of the following
sequences: the sequence of SEQ ID NO.: 1, the
sequence of SEQ ID NO.: 2, the sequence of SEQ ID
NO.: 3 or a sequence which is at least 90%
identical to the sequence of SEQ ID NO.: 3, the
10 sequence of SEQ ID NO.: 4, the sequence of SEQ ID
NO.: 5 or a sequence which is at least 90%
identical to the sequence of SEQ ID NO.: 5, the
sequence of SEQ ID NO.: 6 or a sequence which is
at least 90% identical to the sequence of SEQ ID
15 NO.: 6, the sequence of SEQ ID NO.: 7 or a
sequence which is at least 70% identical to the
sequence of SEQ ID NO.: 7, the sequence of SEQ ID
NO.: 8 or a sequence which is at least 70%
identical to the sequence of SEQ ID NO.: 8, the
20 sequence of SEQ ID NO.: 9 or a sequence which is
at least 70% identical to the sequence of SEQ ID
NO.: 9, the sequence of SEQ ID NO.: 10 or a
sequence which is at least 70% identical to the
sequence of SEQ ID NO.: 10, the sequence of SEQ ID
25 NO.: 11 or a sequence which is at least 70%
identical to the sequence of SEQ ID NO.: 11, the
sequence of SEQ ID NO.: 12 or a sequence which is
at least 60% identical to the sequence of SEQ ID
NO.: 12, the sequence of SEQ ID NO.: 13 or a
30 sequence which is at least 60% identical to the
sequence of SEQ ID NO.: 13, the sequence of SEQ ID
NO.: 14 or a sequence which is at least 75%
identical to the sequence of SEQ ID NO.: 14, the
sequence of SEQ ID NO.: 15 or a sequence which is
35 at least 95% identical to the sequence of SEQ ID
NO.: 15, the sequence of SEQ ID NO.: 16 or a
sequence which is at least 95% identical to the

sequence of SEQ ID NO.: 16, the sequence of SEQ ID NO.: 17 or a sequence which is at least 75% identical to the sequence of SEQ ID NO.: 17, the sequence of SEQ ID NO.: 18 or a sequence which is at least 70% identical to the sequence of SEQ ID NO.: 18, the sequence of SEQ ID NO.: 19 or a sequence which is at least 70% identical to the sequence of SEQ ID NO.: 19, the sequence of SEQ ID NO.: 20 or a sequence which is at least 60% identical to the sequence of SEQ ID NO.: 20, the sequence of SEQ ID NO.: 21 or a sequence which is at least 90% identical to the sequence of SEQ ID NO.: 21, the sequence of SEQ ID NO.: 22 or a sequence which is at least 70% identical to the sequence of SEQ ID NO.: 22, the sequence of SEQ ID NO.: 23 or a sequence which is at least 55% identical to the sequence of SEQ ID NO.: 23, the sequence of SEQ ID NO.: 24 or a sequence which is at least 65% identical to the sequence of SEQ ID NO.: 24, the sequence of SEQ ID NO.: 25 or a sequence which is at least 55% identical to the sequence of SEQ ID NO.: 25, the sequence of SEQ ID NO.: 26 or a sequence which is at least 55% identical to the sequence of SEQ ID NO.: 26, the sequence of SEQ ID NO.: 27 or a sequence which is at least 55% identical to the sequence of SEQ ID NO.: 27, the sequence of SEQ ID NO.: 28 or a sequence which is at least 75% identical to the sequence of SEQ ID NO.: 28, the sequence of SEQ ID NO.: 29 or a sequence which is at least 70% identical to the sequence of SEQ ID NO.: 29, the sequence of SEQ ID NO.: 30 or a sequence which is at least 60% identical to the sequence of SEQ ID NO.: 30, the sequence of SEQ ID NO.: 31 or a sequence which is at least 55% identical to the sequence of SEQ ID NO.: 31, the sequence of SEQ ID NO.: 32 or a sequence which is at least 55%

identical to the sequence of SEQ ID NO.: 32, the sequence of SEQ ID NO.: 33 or the sequence of SEQ ID NO.: 34.

5